Furthermore, recombinant human IL-1 receptor antagonists (rHIL-1RAs) alleviate liver inflammation and reduce NLRP3, caspase-1, and IL-1β production in hepatocytes by scavenging ROS and inhibiting pyroptosis (Luan et al., 2018), suggesting that the NLRP3 inflammasome may be a potential therapeutic target for AIH. Here, NLRP3 is linked to Hepatitis.